NSE · Healthcare · Drug Manufacturers - General
EPS came in at 44.69 against a street estimate of 45.10 — a miss of 0.9%.
with an average price target of ₹6,008.50.
| Document | Date |
|---|---|
| Annual report FY2026 PFIZER LIMITED - SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from operations: ₹2,520 Crore in FY 2026, up 10.4% year-on-year • Net sales | 2026-07-06 |
| Quarterly results · Q4 FY26 PFIZER LIMITED – FINANCIAL SUMMARY Board Meeting: May 12, 2026 --- HEADLINE NUMBERS • Revenue from operations (FY 2025-26): ₹2,519.65 crore (vs ₹2, | 2026-05-12 |
| Quarterly results | 2026-04-13 |
| Quarterly results · Q3 FY26 PFIZER LIMITED – FINANCIAL SUMMARY (Q3 & 9M FY2025-26) HEADLINE NUMBERS • Q3 FY2025-26 Revenue from Operations: ₹645.03 crore (vs ₹642.34 crore in Q | 2026-02-09 |
| Quarterly results · Q2 FY26 PFIZER LIMITED – FINANCIAL SUMMARY (H1 FY2025-26) HEADLINE NUMBERS • Revenue from operations (6 months): ₹1,245.39 crore (vs ₹1,151.45 crore in H1 F | 2025-11-12 |
| Quarterly results · Q1 FY26 PFIZER LIMITED - Q1 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations (Q1 FY26): ₹603.05 crore, up from ₹591.91 crore in Q4 FY25 a | 2025-08-13 |
| Annual report FY2025 PFIZER LIMITED – ANNUAL REPORT SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Sales FY2025: ₹2,128.36 Crore (growth of 2.3% year-over-year) • Profi | 2025-06-29 |
| Quarterly results | 2025-01-31 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹75 / share ex-date Jul 17, 2026 | 2026-07-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pfizer Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.